Myovant Sciences
→
Sumitovant Biopharma (Sumitomo Pharma)
Acquisition · Cash + Stock · SMTOY · announced Oct 24, 2022
Announced
Oct 24, 2022
Closed
Mar 10, 2023
Economics
Cash + Stock()
Pre-deal · pre-deal mark: 2022, year precision · rounding grid ±$100M · Sumitovant press release — Myovant Sciences acquisition, 2023 (NYSE:MYOV market cap)
$27/share for outstanding minority (~$1.7B); total company value ~$2.9B fully diluted; Sumitovant already owned ~52%
Target
Myovant Sciences
Reproductive Health · Clinical / therapeutic
HQ Basel, Switzerland · Founded 2016
Women's health and oncology pharma — Myfembree (relugolix combo for uterine fibroids and endometriosis pain) and Orgovyx (prostate cancer); first oral GnRH antagonist combination approved for women's health
- Sumitomo Pharma press release (Oct 24, 2022)
- PR Newswire — Sumitovant announcement (Oct 2, 2022)
- Business Wire — completion announcement (Mar 10, 2023)
Acquirer
Sumitovant Biopharma (Sumitomo Pharma) (SMTOY)
Reproductive Health
HQ New York, NY
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Myfembree (relugolix combo) is first oral GnRH antagonist approved for uterine fibroids and endometriosis pain — combines with Orgovyx prostate cancer franchise under Sumitomo umbrella
Evidence ladder
Secondary (press / IR)
Sumitomo Pharma press release (Oct 24, 2022)
Secondary (press / IR)
Business Wire — completion announcement (Mar 10, 2023)
Limitations
- Citations are press/IR only — two wires of the same announcement are not dual-source. Add a primary filing.
- $27/share for outstanding minority (~$1.7B); total company value ~$2.9B fully diluted; Sumitovant already owned ~52%
- Pre-deal valuation sourced from: Sumitovant press release — Myovant Sciences acquisition, 2023 (NYSE:MYOV market cap). Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Reproductive Health
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.
| Why included | ||||
|---|---|---|---|---|
| Generate Life Sciences | CooperSurgical (CooperCompanies) | Nov 10, 2021 | value band |
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Vs this deal | ||||
|---|---|---|---|---|
| Forendo Pharma | Organon | Nov 11, 2021 |
Other verified deals by Sumitovant Biopharma (Sumitomo Pharma)
Acquirer program history not already listed as a valuation peer or adjacency row.
No further verified deals
Other verified transactions by Sumitovant Biopharma (Sumitomo Pharma) are already listed above, or none are in the dataset.
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — Myovant Sciences (Reproductive Health). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v11 · updated 2026-10-19 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.